Navarro MA, Villabona CM, Blanco A, Gomez JM, Bonnin RM, Soler J. Salivary excretory pattern of testosterone in substitutive therapy with testosterone enanthate.
Fertil Steril 1994;
61:125-8. [PMID:
8293826 DOI:
10.1016/s0015-0282(16)56464-4]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
OBJECTIVE
To determine salivary and serum T levels by an RIA method after a single injection of 250 mg IM of commercially available T enanthate.
DESIGN
Research study.
SETTING
Patients attended in a hospital environment.
PATIENTS
Sixteen men with secondary hypogonadism.
INTERVENTIONS
Testosterone enanthate was administered, and salivary samples were taken before the injection. Thereafter, these samples were obtained daily until day 7 and then on alternate days until day 28 after injection. Blood samples were taken previously and after the injection (5 samples during the month).
MAIN OUTCOME MEASURE
Salivary and serum T.
RESULTS
Salivary T levels rose from 3.46 +/- 3.16 to 13.82 +/- 7.78 ng/100 mL (0.12 +/- 0.11 to 0.48 +/- 0.27 nmol/L) within 24 hours and remained in that range until day 7. From day 9, 7.20 +/- 2.88 ng/100 mL (0.25 +/- 0.10 nmol/L), a progressive decrease of these values was observed until day 14: 5.18 +/- 2.88 ng/100 mL (0.18 +/- 0.10 nmol/L). From day 16 until day 28, salivary concentrations returned to hypogonadal levels.
CONCLUSION
We conclude that T salivary concentrations may be applied to assess the effectiveness of T substitutive therapy in hypogonadal men and could replace serum in the monitoring of this type of therapy.
Collapse